Abstract
Stereotactic body radiotherapy (SBRT) has firmly established its role in the management of stage I non-small cell lung cancer (NSCLC). Results from trials are difficult to generalize to the entire patient population in the real world. In addition, in contrast to trials, real-world data provides increased statistical power to study rare outcomes and their predictors. The primary aim of this nationwide study was to determine the real-world incidence of acute toxicity and 90-day mortality in patients treated with SBRT for stage I NSCLC.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call